Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Neuroblastoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 61 for your search:
Start Over
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2009-01064, CDR0000069018, COG-ANBL0032, ANBL0032, U10CA180886, U10CA030969, U10CA098543, COG-P9842, NCT00026312
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 17 months and under
Sponsor: NCI, Other
Protocol IDs: ANBL1232, NCI-2014-00677, U10CA098543, U10CA180886, NCT02176967
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: 05-075, NCT00911560
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Study of MLN8237 in Combination With Irinotecan and Temozolomide
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 30
Sponsor: Other
Protocol IDs: N2009-03, NCT01601535
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PST-001, NCT01962103
WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2014-00547, ADVL1312, UM1CA097452, NCT02095132
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: NMTRC010, NCT02139397
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 moths to 29 years
Sponsor: NCI, Other
Protocol IDs: 2013-171, NCI-2014-01149, P30CA022453, NCT02173093
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-01222, ADVL1412, UM1CA097452, NCT02304458
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, P30CA015704, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: NCI
Protocol IDs: 04-148, MSKCC-04148, NCT00107289
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 years and under
Sponsor: Other
Protocol IDs: IRB# 0405652, NCT00202930
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: V0706, NCT00601003
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: 11-183, NCT01492673
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
Therapy for Children With Advanced Stage Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NB2012, NCI-2013-00034, NCT01857934
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116731, NCT01956669
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 24 months to less than 30 years
Sponsor: Other
Protocol IDs: N2011-01, NCT02035137
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: STIR Trial, NCT02100891
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 25
Sponsor: NCI, Other
Protocol IDs: 13-443, NCT02112617
Start Over